Frontline Fixed-Duration Acalabrutinib Plus Venetoclax in Rapidly Progressive _IGHV_-Mutated CLL: A Case Report
# Introduction The phase III AMPLIFY trial established fixed-duration acalabrutinib plus venetoclax as an effective, all-oral, chemotherapy-free frontline therapy for chronic lymphocytic leukemia (CLL). We report the real-world use of this regimen in a patient with rapidly progressive _IGHV_-mutate...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
THE HEALTHBOOK COMPANY LTD.
2026-05-01
|
| Col·lecció: | healthbook TIMES. Oncology Hematology |
| Accés en línia: | https://doi.org/10.36000/HBT.OH.2026.28.208 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|